⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8118840 | 1.00 | — | — | |
| SCHEMBL2400739 | 1.00 | — | — | |
| SCHEMBL29389040 | 0.86 | ALDH1A1 (0.37) | — | |
| SCHEMBL11724877 | 0.86 | ALDH1A1 (0.37) | — | |
| SCHEMBL1517004 | 0.85 | GNAI3 (0.44) | — | |
| SCHEMBL1412127 | 0.83 | MCHR1 (0.43) | — | |
| SCHEMBL1412129 | 0.83 | MCHR1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL3286216 | 0.83 | GNAI3 (0.47) | — | |
| Hydrochloric Acid SCHEMBL4120587 | 0.83 | GNAI3 (0.47) | — | |
| SCHEMBL798194 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4499656-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119183453-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| WO-2023192960-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192960-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-3406142-B1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | CELGENE INT II SARL (CH) | 2020-12-23 | — | — | EP | disclosed |
| EP-2706999-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2019-08-28 | — | — | EP | disclosed |
| EP-2498609-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2018-04-18 | — | — | EP | disclosed |
| WO-2018064356-A1 | COMPOUNDS AND METHODS FOR TREATING LUPUS | CELGENE INTERNATIONAL II SARL (CH) | 2018-04-05 | — | — | WO | disclosed |
| WO-2012158550-A9 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2015066515-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH | RECEPTOS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011060392-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |